PT - JOURNAL ARTICLE AU - Chen, Holly Y. AU - Swaroop, Manju AU - Papal, Samantha AU - Mondal, Anupam K. AU - Tawa, Gregory J. AU - Regent, Florian AU - Shimada, Hiroko AU - Nagashima, Kunio AU - de Val, Natalia AU - Jacobson, Samuel G. AU - Zheng, Wei AU - Swaroop, Anand TI - Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects AID - 10.1101/2022.09.14.22279917 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.14.22279917 4099 - http://medrxiv.org/content/early/2022/09/18/2022.09.14.22279917.short 4100 - http://medrxiv.org/content/early/2022/09/18/2022.09.14.22279917.full AB - Ciliopathies manifest from sensory abnormalities to syndromic disorders with multiorgan pathologies, with retinal degeneration a highly penetrant phenotype. Photoreceptor cell death is a major cause of incurable blindness in retinal ciliopathies. To identify drug candidates to maintain photoreceptor survival, we performed an unbiased, high-throughput screening of over 6,000 bioactive small molecules using retinal organoids differentiated from induced pluripotent stem cells (iPSC) of rd16 mouse, which is a model of Leber congenital amaurosis (LCA)10 caused by mutations in the cilia-centrosomal gene CEP290. We identified five non-toxic positive hits, including the lead molecule reserpine, which improved photoreceptor survival in rd16 organoids. Reserpine also maintained photoreceptors in retinal organoids derived from induced pluripotent stem cells of LCA10 patients and in rd16 mouse retina in vivo. Reserpine-treated patient organoids revealed modulation of signaling pathways related to cell survival/death, metabolism, and proteostasis. Further investigation uncovered misregulation of autophagy associated with compromised primary cilium biogenesis in patient organoids and rd16 mouse retina. Reserpine partially restored the balance between autophagy and the ubiquitin-proteasome system, at least in part by increasing the cargo adaptor p62 and improving primary cilium assembly. Our study identifies effective drug candidates in preclinical studies of CEP290 retinal ciliopathies through cross-species drug discovery using iPSC-derived organoids, highlights the impact of proteostasis in the pathogenesis of ciliopathies, and provides new insights for treatments of retinal neurodegeneration.Competing Interest StatementHYC, MS, SP, AJM, GT, WZ and AS are listed as inventors on a patent application related to the small molecules in this study by National Institutes of Health. Other authors declare that they have no competing interests.Funding StatementThe work was supported by National Eye Institute Intramural Research Programs (ZIAEY000450 and ZIAEY000546) and National Center for Advancing Translational Sciences Intramural Research Programs ZIATR000018-06.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:After written informed consent, biopsy specimens were obtained from LCA patients and unaffected families controls. The study followed the tenets of the Declaration of Helsinki and was approved by University of Pennsylvania institutional review board (IRB) protocol 183400 (to Dr. Samuel G. Jacobson), a co-author on this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. RNA-seq data are available through GEO accession #206959.